Journal article

Publication year: 2019

Journal: Therapeutic Advances in Respiratory Disease

Volume number: 13

ISSN: 1753-4658

eISSN: 1753-4666

Open access status: Gold

DOI Link: https://doi.org/10.1177/1753466619835497

Publisher: SAGE Publications

Abstract: 
Inhaled iloprost is a well-established medication to treat pulmonary arterial hypertension (PAH), a serious and potentially fatal disease of the pulmonary resistance vessels. The therapeutic administration of iloprost requires six to nine inhalations per day, due to the short biological half-life of this prostacyclin analogue. The I-Neb(TM) AAD(TM), introduced in 2006, is the most commonly used nebulizer for delivering iloprost, requiring at least 6.5 min for an inhaled dose of 5 mu g. In order to reduce inhalation time, a portable nebulizer based on modern-device technology was developed. The acute safety and tolerability of rapid iloprost inhalation via the BREELIBTM nebulizer was assessed in a four-part clinical trial. In this review, I describe the rationale and features of the new nebulizer, with particular emphasis on the safety and tolerability profile of iloprost inhalation via BREELIBTM observed in the first clinical studies. Meanwhile, the BREELIBTM nebulizer is approved and available for inhaled iloprost therapy combining significantly reduced inhalation time with good tolerability. This new approach will certainly improve patient convenience and compliance, possibly resulting in broader acceptance and improved efficacy of iloprost aerosol therapy in PAH. The reviews of this paper are available via the supplementary material section.

Harvard Citation style: Gessler, T. (2019) lloprost delivered via the BREELIB^TM nebulizer: a review of the clinical evidence for efficacy and safety, Therapeutic Advances in Respiratory Disease, 13, Article 1753466619835497. https://doi.org/10.1177/1753466619835497

APA Citation style: Gessler, T. (2019). lloprost delivered via the BREELIB^TM nebulizer: a review of the clinical evidence for efficacy and safety. Therapeutic Advances in Respiratory Disease. 13, Article 1753466619835497. https://doi.org/10.1177/1753466619835497